EUROPE MALE INFERTILITY MARKET FORECAST 2023-2032

The Europe male infertility market growth evaluation includes a thorough study of Poland, Italy, the United Kingdom, Belgium, Germany, Spain, France, and Rest of Europe. The male infertility market in the United Kingdom is expected to witness growth, propelled by several key factors. The increasing prevalence of diabetes and obesity and habits such as smoking, drinking, and consumption of illegal drugs contribute to male infertility. Diabetes, in particular, adversely affects sperm quality, DNA integrity, motility, and seminal plasma components. 

The United Kingdom has seen a rise in diabetes cases, with over 150,000 more individuals diagnosed in 2021 compared to 2020. Moreover, over 13.6 million people are at a higher risk of developing type 2 diabetes in the country. By 2030, it is projected that there will be 5.5 million people worldwide with diabetes, excluding those who remain undiagnosed. These factors collectively shape the landscape of the male infertility market in the United Kingdom, influencing its growth during the forecast period.

On the other hand, the prevalence of male infertility in Germany is rising due to various factors, including changes in diet, lifestyle, and pollution levels. Cases of reduced sperm count have significantly increased, contributing to the overall rise in male infertility cases. Prostate cancer, the most common malignancy in men in Germany, is also a driving factor for the market expansion. 

With advancements in therapeutic techniques, the Urology Departments nationally are at the forefront of treating male infertility. German centers specializing in reproduction and clinical embryology offer comprehensive examinations and evaluations. Furthermore, increased research and development efforts, such as the University of Münster’s discovery of the M1AP gene, hold promise for developing new tests and further market growth in Germany.

The Europe male infertility market segmentation entails the evaluation by test type and treatment. Market by test type includes sperm agglutination, oxidative stress analysis, computer-assisted semen analysis, DNA fragmentation technique, sperm penetration assay, microscopic examination, and other test types.

The analysis of oxidative stress is a crucial test that greatly influences male infertility and the normal development of embryos. Fertility experts are increasingly focusing on oxidative stress analysis and exploring methods to diagnose and treat it using antioxidants. Studies indicate that elevated levels of reactive oxygen species (ROS) in the seminal fluid are present in a significant percentage of infertile men (30% to 80%), highlighting the role of oxidative stress in male infertility. 

Oxidative stress negatively impacts fertility through various mechanisms, including interference with capacitation, DNA damage, and sperm membrane impairment, which can hinder a sperm’s ability to fertilize an egg. Thus, evaluating sperm oxidative stress is vital for assessing male reproductive potential. Market players worldwide have made significant advancements in oxidative stress technology, expected to contribute positively to market growth in the forecast period.

Leading companies in the Europe male infertility market are Andrology Solutions, Endo International PLC, Vitrolife, etc.

Endo International PLC is an Ireland-based multinational specialty pharmaceutical company dedicated to improving patients’ quality of life. With subsidiaries including Par Pharmaceutical, Endo Pharmaceuticals, and Paladin Labs, it develops, produces, and distributes high-quality branded and generic pharmaceutical products globally. Endo is headquartered in Dublin, Ireland.

One of its offerings is Aveed, an androgen injection for testosterone replacement therapy in adult males with testosterone deficiency conditions.